Mitomycin C provides little additional benefit in the treatment of carcinoma of unknown primary site

Affiliations

Comment

Jonathan E Dowell. Cancer Treat Rev. 2003 Dec.

. 2003 Dec;29(6):561-3.

doi: 10.1016/j.ctrv.2003.09.001.

¹ University of Texas-Southwestern Medical Center, University of Texas-Southwestern, Dallas, TX, USA. jonathan.dowell@utsouthwestern.edu

No abstract available

Comment on

A randomised study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary.
Assersohn L, Norman AR, Cunningham D, Iveson T, Seymour M, Hickish T, Massey A, Prior Y, Hill ME. Assersohn L, et al. Eur J Cancer. 2003 May;39(8):1121-8. doi: 10.1016/s0959-8049(03)00150-3. Eur J Cancer. 2003. PMID: 12736112 Clinical Trial.